CCCC
C4 Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.77
+0.67%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−2.7x
Market Cap
$463.19M
MomentumView details →
1D Return
+0.67%
YTD Return
+95.55%
RSI (14)
43.9
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−2.7x
Market Cap
$463.19M
RSI (14)
43.9
MomentumView details →
1D Return
+0.67%
YTD Return
+95.55%
SummaryUpdated Jun 1, 2026
C4 Therapeutics, Inc. (NASDAQ:CCCC) is a clinical-stage biopharmaceutical company founded in 2015 and headquartered in Watertown, Massachusetts. The company went public in October 2020 and focuses on developing innovative cancer treatments using a novel approach called targeted protein degradation. C4 Therapeutics has established strategic partnerships with major pharmaceutical companies including Roche, Biogen, and Calico Life Sciences to advance its pipeline of experimental drugs through clinical trials.
Similar companies
Latest newsMore news →